Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020

July 2020 | 667 pages | ID: A7655ACCBB1EN
Global Markets Direct

Abstracts

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.
Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 28, 22, 4, 50, 16 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Acute Respiratory Distress Syndrome - Overview
Acute Respiratory Distress Syndrome - Therapeutics Development
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Acute Respiratory Distress Syndrome - Drug Profiles
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by AbbVie Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Abivax SA, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Aerogen Ltd, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Akebia Therapeutics Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Ampio Pharmaceuticals Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by APEIRON Biologics AG, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Apellis Pharmaceuticals Inc, H2 2020
Acute Respiratory Distress Syndrome - Pipeline by Xfibra Inc, H2 2020
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2020
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

A6 Pharmaceuticals LLC
AbbVie Inc
Abivax SA
Aerogen Ltd
Aerpio Pharmaceuticals Inc
Akebia Therapeutics Inc
Alexion Pharmaceuticals Inc
Algernon Pharmaceuticals Inc
Ampio Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
APEIRON Biologics AG
Apellis Pharmaceuticals Inc
Apeptico Forschung und Entwicklung GmbH
Aptahem AB
Aqualung Therapeutics Corp
Arch Biopartners Inc
Argenx SE
Athersys Inc
Ayuvis Research Inc
Bayer AG
Baylx Inc
BeiGene Ltd
BioCardia Inc
Biocon Ltd
BioMarck Pharmaceuticals Ltd
Biophytis SA
BioStem Technologies Inc
Biotest AG
Biovista Inc
Bioxytran Inc
Bonac Corp
Bonus BioGroup Ltd
BrainStorm Cell Therapeutics Inc
CarthroniX Inc
Ceapro Inc
Cellenkos Inc
Cellresearch Corp Pte Ltd
Celularity Inc
Cerecor Inc
Chiesi Farmaceutici SpA
China Grand Pharmaceutical and Healthcare Holdings Ltd
CohBar Inc
Commence Bio Inc
Curacle Co Ltd
Cynata Therapeutics Ltd
Cytopeutics Pte Ltd
Diffusion Pharmaceuticals Inc
Dimerix Ltd
Edesa Biotech Inc
Educell doo
Emergent BioSolutions Inc
Emtora Biosciences
Enzychem Lifesciences Corp
Eunoia Biotech LLC
EUSA Pharma (UK) Ltd
Evgen Pharma Plc
Exvastat Ltd
F4 Pharma GmbH
Faron Pharmaceuticals Oy
FibroGenesis LLC
Foresee Pharmaceuticals Co Ltd
Grifols SA
Hemarina SA
Histocell SL
Human Life CORD Japan Inc
Hydra Biosciences Inc
Iltoo Pharma
Immune Regulation Ltd
IMMvention Therapeutix Inc
Implicit Bioscience Ltd
Impression Healthcare Ltd
Imstem Biotechnology Inc
In2cure AB
Insmed Inc
IsletOne AB
Khondrion BV
Koligo Therapeutics Inc
Kubota Vision Inc
Kyorin Pharmaceutical Co Ltd
Lamellar Biomedical Ltd
Lattice Biologics Ltd
Leading BioSciences Inc
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
MannKind Corp
Matrix Biomed Inc
Meridigen Biotech Co Ltd
Mesoblast Ltd
Nano Biotherapeutics Inc
NantKwest Inc
Neutrolis Inc
Northern Therapeutics Inc
Novellus Inc
Noxopharm Ltd
NS Pharma Inc
Orbsen Therapeutics Ltd
Oryzon Genomics SA
PharmAbcine Inc
Pharming Group NV
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Predictive Biotech Inc
R Pharm
Relief Therapeutics Holding AG
Restore Therapeutics LLC
Reven Pharmaceuticals Inc
Roivant Sciences Ltd
Santhera Pharmaceuticals Holding AG
Savara Inc
SFA Therapeutics LLC
SolAeroMed Inc
SynAct Pharma AB
Syndax Pharmaceuticals Inc
Thetis Pharmaceuticals LLC
Trevena Inc
Vasomune Inc
Veru Inc
Windtree Therapeutics Inc
Xfibra Inc